Yi Sun-Ju, Jang You-Jee, Kim Hye-Jung, Lee Kyubin, Lee Hyerim, Kim Yeojin, Kim Junil, Hwang Seon Young, Song Jin Sook, Okada Hitoshi, Park Jae-Il, Kang Kyuho, Kim Kyunghwan
Department of Biological Sciences and Biotechnology, Chungbuk National University, Cheongju, Chungbuk, Republic of Korea.
Korea Basic Science Institute, Gwangju Center at Chonnam National University, Gwangju, Republic of Korea.
Bone Res. 2021 May 25;9(1):27. doi: 10.1038/s41413-021-00145-1.
Bone undergoes a constant and continuous remodeling process that is tightly regulated by the coordinated and sequential actions of bone-resorbing osteoclasts and bone-forming osteoblasts. Recent studies have shown that histone demethylases are implicated in osteoblastogenesis; however, little is known about the role of histone demethylases in osteoclast formation. Here, we identified KDM4B as an epigenetic regulator of osteoclast differentiation. Knockdown of KDM4B significantly blocked the formation of tartrate-resistant acid phosphatase-positive multinucleated cells. Mice with myeloid-specific conditional knockout of KDM4B showed an osteopetrotic phenotype due to osteoclast deficiency. Biochemical analysis revealed that KDM4B physically and functionally associates with CCAR1 and MED1 in a complex. Using genome-wide chromatin immunoprecipitation (ChIP)-sequencing, we revealed that the KDM4B-CCAR1-MED1 complex is localized to the promoters of several osteoclast-related genes upon receptor activator of NF-κB ligand stimulation. We demonstrated that the KDM4B-CCAR1-MED1 signaling axis induces changes in chromatin structure (euchromatinization) near the promoters of osteoclast-related genes through H3K9 demethylation, leading to NF-κB p65 recruitment via a direct interaction between KDM4B and p65. Finally, small molecule inhibition of KDM4B activity impeded bone loss in an ovariectomized mouse model. Taken together, our findings establish KDM4B as a critical regulator of osteoclastogenesis, providing a potential therapeutic target for osteoporosis.
骨骼经历着持续不断的重塑过程,该过程受到破骨细胞(负责骨吸收)和成骨细胞(负责骨形成)协同且有序作用的严格调控。最近的研究表明,组蛋白去甲基化酶与成骨细胞生成有关;然而,关于组蛋白去甲基化酶在破骨细胞形成中的作用却知之甚少。在此,我们确定KDM4B是破骨细胞分化的一种表观遗传调节因子。敲低KDM4B可显著阻断抗酒石酸酸性磷酸酶阳性多核细胞的形成。骨髓特异性条件性敲除KDM4B的小鼠由于破骨细胞缺乏而表现出骨质石化表型。生化分析表明,KDM4B在一个复合物中与CCAR1和MED1在物理和功能上相关联。通过全基因组染色质免疫沉淀(ChIP)测序,我们发现,在核因子κB受体激活剂配体刺激后,KDM4B - CCAR1 - MED1复合物定位于几个破骨细胞相关基因的启动子上。我们证明,KDM4B - CCAR1 - MED1信号轴通过H3K9去甲基化诱导破骨细胞相关基因启动子附近的染色质结构变化(常染色质化),导致通过KDM4B与p65之间的直接相互作用招募NF - κB p65。最后,小分子抑制KDM4B活性可阻止去卵巢小鼠模型中的骨质流失。综上所述,我们的研究结果确定KDM4B是破骨细胞生成的关键调节因子,为骨质疏松症提供了一个潜在的治疗靶点。